HC Wainwright Issues Negative Estimate for TNGX Earnings

Tango Therapeutics, Inc. (NASDAQ:TNGX) – Analysts at HC Wainwright decreased their Q3 2026 EPS estimates for Tango Therapeutics in a research note issued on Tuesday, August 18th. HC Wainwright analyst R. Burns now expects that the company will post earnings per share of ($0.32) for the quarter, down from their prior estimate of ($0.26). HC Wainwright has a “Buy” rating and a $68.00 price objective on the stock. The consensus estimate for Tango Therapeutics’ current full-year earnings is ($1.36) per share. HC Wainwright also issued estimates for Tango Therapeutics’ Q4 2026 earnings at ($0.34) EPS, FY2026 earnings at ($1.34) EPS and Q1 2027 earnings at ($0.35) EPS.

Tango Therapeutics (NASDAQ:TNGX) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.05).

Several other brokerages have also issued reports on TNGX. Wedbush increased their price target on Tango Therapeutics from $19.00 to $33.00 and gave the stock an “outperform” rating in a report on Thursday, May 14th. Wolfe Research set a $35.00 target price on Tango Therapeutics and gave the stock an “outperform” rating in a research report on Monday, June 8th. Guggenheim increased their target price on Tango Therapeutics from $32.00 to $35.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Piper Sandler downgraded shares of Tango Therapeutics from an “overweight” rating to a “neutral” rating and lifted their price target for the company from $16.00 to $24.00 in a research report on Thursday, May 14th. Finally, Raymond James Financial lowered shares of Tango Therapeutics to a “hold” rating in a research note on Thursday, June 25th. Thirteen research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $43.46.

Tango Therapeutics Price Performance

Shares of Tango Therapeutics stock opened at $25.20 on Thursday. Tango Therapeutics has a one year low of $6.25 and a one year high of $34.39. The firm has a market capitalization of $4.25 billion, a price-to-earnings ratio of -29.65 and a beta of 1.16. The business has a 50-day simple moving average of $28.62 and a 200 day simple moving average of $22.61.

Insider Activity

In other news, insider Adam Crystal sold 27,000 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $29.59, for a total value of $798,930.00. Following the completion of the sale, the insider owned 115,743 shares in the company, valued at $3,424,835.37. This represents a 18.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 6.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Tango Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Allworth Financial LP bought a new position in shares of Tango Therapeutics during the 2nd quarter worth approximately $35,000. Global Retirement Partners LLC bought a new position in Tango Therapeutics in the 2nd quarter valued at $122,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Tango Therapeutics by 148,800.0% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,467 shares of the company’s stock worth $40,000 after purchasing an additional 4,464 shares during the period. ANTIPODES PARTNERS Ltd purchased a new position in shares of Tango Therapeutics in the 4th quarter worth about $40,000. Finally, State of Wyoming bought a new position in Tango Therapeutics during the first quarter valued at about $128,000. 78.99% of the stock is owned by institutional investors.

More Tango Therapeutics News

Here are the key news stories impacting Tango Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its price target for TNGX to $68 from $66 and reiterated a Buy rating. The new target implies substantial upside from the referenced $25.20 share price, providing a positive valuation signal for investors. HC Wainwright Increases Tango Therapeutics Price Target to $68
• Positive Sentiment: The analyst’s long-term outlook remains constructive, with projected 2027 quarterly losses of $0.37 to $0.41 per share and a full-year loss estimate of $1.54 per share, while maintaining the Buy rating and $68 target.
• Neutral Sentiment: HC Wainwright expects Tango Therapeutics to remain unprofitable through 2026 and 2027, forecasting fiscal 2026 EPS of negative $1.34 and fiscal 2027 EPS of negative $1.54. These estimates reinforce the company’s development-stage profile and suggest that investor sentiment will remain tied to clinical and pipeline progress rather than current earnings.
• Negative Sentiment: HC Wainwright reduced its fiscal 2026 EPS forecast to negative $1.34 from negative $1.15. It also cut its third-quarter estimate to negative $0.32 from negative $0.26 and its fourth-quarter estimate to negative $0.34 from negative $0.27, indicating higher anticipated losses than previously expected.

Tango Therapeutics Company Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.